An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density

PHASE3CompletedINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

May 1, 2006

Primary Completion Date

March 28, 2011

Study Completion Date

August 2, 2012

Conditions

Low Bone Mineral Density

Interventions

DRUG

AMG 162

AMG 162; 60 mg/mL of Denosumab given to all subjects at Screening/Day 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36 and Month 42